[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_MaterialEventDisclosureGeneralAbstract|
Material Event Disclosure General
oda_UpdateAnnouncementFlag|
Update Notification Flag
Evet (Yes)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
19.02.2024
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.(GEN) disclosed on February 19, 2024 ( https://www.kap.org.tr/en/Bildirim/1250351 ) Phase 1 clinical trials was started for SUL-238, our innovative drug research project which developed for the treatment of Alzheimer's and other neurodegenerative diseases. The results of these Phase 1 clinical trials have been presented at the 2025 Alzheimer's Association International Conference (AAIC 2025) in Toronto.

Announced results indicates that SUL-238 is safe and well-tolerated in healthy volunteers, and its high ability to cross the blood-brain barrier indicates significant promise for the treatment of neurodegenerative diseases. Detailed Phase 1 clinical trial results are accessible on GEN's corporate website.

In Phase 1 clinical trials, drugs are tested for the first time in humans, particularly to assess their safety and pharmacokinetic properties (such as post-administration blood concentrations, half-life, and bioavailability), using 20–80 healthy volunteers.

Thanks to the successful completion of our Phase 1 clinical trials, the path has been cleared for the clinical development of SUL-238 in patient populations.